Complement and kidney diseases: unlocking the opportunity of targeted treatments for glomerular diseases, including IgA nephropathy
Pediatric Nephrology · 2026
DOI: 10.1007/s00467-026-07166-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pediatric Nephrology, 2026. Verfasst von Joshua Wade und 3 weiteren Autor:innen. Beteiligte Einrichtung: Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Complement System Proteins, Complement Activation, Complement Inactivating Agents. Die Arbeit nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The imminent availability of multiple therapeutic complement inhibitors, which target different complement pathway components, could revolutionise treatment for a broad range of kidney diseases. However, the complexity of complement activity within and between kidney diseases, for which IgA nephropathy is an illustrative example, and the possible adverse effects of complement inhibition mean robust patient selection and stratification to appropriately targeted inhibitors will be needed to maximise this therapeutic opportunity. Despite promising candidates, novel biomarkers that stratify patients to targeted complement inhibition have not yet been validated for clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
- Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK.
- Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, UK. n.medjeral-thomas@imperial.ac.uk.
- Respiratory, Immunology and Inflammation Research Unit, Medicine Research Centre, GSK, Stevenage, UK. n.medjeral-thomas@imperial.ac.uk.
Zitieren
APA
Wade, J., Thomas, D. C., Pickering, M. C., & Medjeral-Thomas, N. R. (2026). Complement and kidney diseases: unlocking the opportunity of targeted treatments for glomerular diseases, including IgA nephropathy. Pediatric Nephrology. https://doi.org/10.1007/s00467-026-07166-0
Vancouver
Wade J, Thomas DC, Pickering MC, Medjeral-Thomas NR. Complement and kidney diseases: unlocking the opportunity of targeted treatments for glomerular diseases, including IgA nephropathy. Pediatric Nephrology. 2026. doi:10.1007/s00467-026-07166-0
BibTeX
@article{Wade2026,
author = {Wade, Joshua and Thomas, David C and Pickering, Matthew C and Medjeral-Thomas, Nicholas R},
title = {Complement and kidney diseases: unlocking the opportunity of targeted treatments for glomerular diseases, including IgA nephropathy},
journal = {Pediatric Nephrology},
year = {2026},
doi = {10.1007/s00467-026-07166-0}
}
EUVIMED